Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 13/20 | 0.55 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL636110 | 1.00 | EPHX2 (0.55) | EPHX2EPHX1KMT2AMEN1MAPK1 | |
| SCHEMBL636702 | 0.85 | EPHX2 (0.51) | EPHX2EPHX1KMT2AMEN1MAPK1 | |
| SCHEMBL636701 | 0.85 | EPHX2 (0.51) | EPHX2EPHX1KMT2AMEN1MAPK1 | |
| SCHEMBL10216951 | 0.79 | L3MBTL1 (0.39) | EPHX2EPHX1KMT2AMEN1MAPK1 | |
| SCHEMBL14503293 | 0.76 | EPHX2 (0.67) | EPHX2EPHX1KMT2AMEN1LMNA | |
| SCHEMBL635478 | 0.74 | NAAA (0.42) | KMT2AMEN1MAPK1SMN1; SMN2 | |
| SCHEMBL635477 | 0.74 | NAAA (0.42) | KMT2AMEN1MAPK1SMN1; SMN2 | |
| SCHEMBL3069160 | 0.73 | EPHX2 (1.00) | EPHX2EPHX1LMNAHTTL3MBTL1 | |
| SCHEMBL22480390 | 0.73 | EPHX2 (0.67) | EPHX2EPHX1KMT2AMEN1MAPK1 | |
| SCHEMBL13711391 | 0.71 | CA2 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2086995-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-02-22 | — | — | EP | disclosed |
| US-7888464-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-02-15 | — | — | US | disclosed |
| US-20090274648-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090274648-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, HCCS, PYGL | EPHX2 2019/4885EPHX1 1709/4885KMT2A 4486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.